Clinical trials involving 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) using both cIMT and cardiovascular event outcomes
| Clinical Trials | n a | Statin | Relative Impact on IMT Progression of Primary Outcomeb | Relative Impact on Reported Cardiovascular Endpoints | |
|---|---|---|---|---|---|
| Abstracted CVD Events | Odds Ratio (95% CI) | ||||
| mm/yr | |||||
| ACAPS | 919 | Lovastatin | –0.015 (–0.023 to –0.007) (p = 0.001) | CVD death, MI, stroke | 0.34 (0.12–0.69) |
| KAPS | 447 | Pravastatin | –0.014 (–0.022 to –0.006) (p = 0.005) | CVD death, MI, stroke | 0.57 (0.22–1.47) |
| PLAC-II | 151 | Pravastatin | –0.009 (–0.031 to –0.013) (p = 0.44) | Clinical coronary events | 0.37 (0.11–1.24) |
| CAIUS | 305 | Pravastatin | –0.014 (–0.021 to –0.005) (p = 0.0007) | CVD death, MI, stroke | 1.02 (0.14–7.33) |
| REGRESS | 255 | Pravastatin | –0.030 (–0.056 to –0.004) (p = 0.002) | Clinical events | 0.51 (0.24–1.07) |
| BCAPS | 793 | Fluvastatin | –0.008 (–0.013 to –0.003) (p = 0.002) | CVD death, MI, stroke | 0.64 (–0.24 to 1.66) |
| FAST | 164 | Pravastatin | Significant benefit (p < 0.001) | CVD death, MI | 0.32 (0.10–1.06) |
| Pooled estimate | –0.012 (–0.016 to –0.007)c | 0.48 (0.30–0.78) | |||
ACAPS, Asymptomatic Carotid Artery Progression Study; KAPS, Kuopio Atherosclerosis Prevention Study; PLAC-II, Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries; CAIUS, Carotid Atherosclerosis Italian Ultrasound Study; REGRESS, Regression Growth Evaluation Statin Study; BCAPS, Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study; FAST, Fukuoka Atherosclerosis Trial
↵ a Arms used in meta-analyses
↵ b Data are means (95% CI) (reported p value)
↵ c Excludes FAST